If the GH-peptide market has a legitimate aristocrat, it's tesamorelin: FDA-approved since 2010 (Egrifta), with placebo-controlled trials showing real visceral-fat reduction. The asterisk is the population - HIV-associated lipodystrophy - and everything interesting about tesamorelin in 2026 lives in the gap between that label and the longevity clinics prescribing it to everyone else.
What tesamorelin is
Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl modification that resists enzymatic degradation - sermorelin's mechanism with pharmaceutical staying power. Theratechnologies took it through full development to approval for reducing excess abdominal fat in HIV patients with lipodystrophy, where antiretrovirals drive visceral adiposity.
The evidence - genuinely good, genuinely narrow
- Phase 3 trials: ~15-18% visceral adipose tissue reduction over 26 weeks versus placebo, maintained with continued use - real, controlled, replicated.
- Liver: NIH-affiliated research (Stanley et al.) showed reduced liver fat and slowed fibrosis progression in HIV-associated NAFLD - the data behind current metabolic-liver interest.
- Reversal on stopping: VAT returns after discontinuation; like every drug in the metabolic space, it treats while taken.
- General-population data: this is the gap - the trials were in HIV cohorts, and the wellness use extrapolates from them.
On-label, off-label, and gray
Three tiers of tesamorelin use exist. On-label: Egrifta for HIV lipodystrophy - insurable, monitored. Off-label: physicians prescribing branded product for visceral fat or NAFLD outside HIV - legal prescribing judgment, self-pay. Gray: compounded or research-chemical 'tesamorelin' at a fraction of the price - where identity and legality both blur, since compounding copies of an available approved drug faces the same restrictions that hit GLP-1s post-shortage.
The dosage math
The label regimen is 2 mg once daily subcutaneously (original Egrifta; the SV/WR reformulations dose 1.28-1.4 mg with different diluents). Branded product ships with its own reconstitution instructions - follow those over any calculator. For gray-format vials, the standard math applies: a 2 mg vial in 0.5 ml is 4 mg/ml, so 2 mg = 0.5 ml = 50 units.
Side effects and monitoring
Trial-documented: injection-site reactions, joint pain and stiffness, peripheral edema, and - the one that matters - impaired glucose tolerance, since GH antagonizes insulin. The label calls for glucose monitoring; IGF-1 monitoring is standard in practice. Contraindications include active malignancy and pregnancy, and the pituitary axis caveats of any GHRH product.
Frequently asked questions
Does tesamorelin work for belly fat?
In its trials - HIV-associated lipodystrophy - yes: ~15-18% visceral fat reduction versus placebo over 26 weeks. In the general population the same biology plausibly applies but has never been confirmed in a dedicated trial; off-label use rides that extrapolation.
How much does tesamorelin cost?
Branded Egrifta runs at specialty-pharma prices (thousands per month list, insurance-dependent within the label). Off-label self-pay through clinics typically lands in the hundreds per month; gray-market vials cost less and carry the usual identity and legality caveats.
Tesamorelin vs sermorelin - which is better?
Same mechanism, different evidence class: tesamorelin has a current approval and controlled fat-loss trials; sermorelin has a discontinued pediatric approval and small, old adult studies. If evidence drives the choice, it isn't close - which is what the price difference reflects.
Does tesamorelin raise blood sugar?
It can - GH counteracts insulin, and the trials documented impaired glucose tolerance in a subset. That's why the label specifies glucose monitoring, and why anyone with diabetes or prediabetes needs prescriber oversight, not a vial.